Drug · CHEMBL114
SAQUINAVIR
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SAQUINAVIR. Drugs and targets, record CHEMBL114. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL114
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 6 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases6
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| HIV infectious disease | Approval | DailyMed and TTD | 46 | 42 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| HIV-1 infection | Approval | DailyMed | 4 | 3 | https://conductscience.org/library/drugs?q=EFO_0000180 |
| AIDS | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0012268 |
| nephrotoxicity | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0011056 |
| pulmonary arterial hypertension | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0015924 |
| viral infectious disease | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005108 |
Source Open Targets
Trials69
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00035932 | Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV | Phase 3 | 571 | 2010-12-24 | saquinavir | Its name | ClinicalTrials.gov |
| NCT00105079 | GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection | Phase 3 | 337 | 2011-11-02 | saquinavir | Its name | ClinicalTrials.gov |
| NCT00039741 | Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children | Phase 2/3 | 266 | 2012-04-24 | saquinavir | Its name | ClinicalTrials.gov |
| NCT00623597 | A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. | Phase 2 | 18 | 2016-01-14 | saquinavir | Its name | ClinicalTrials.gov |
| NCT00435929 | A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection. | Phase 1 | 16 | 2016-01-08 | saquinavir | Its name | ClinicalTrials.gov |
| NCT00002382 | A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients | Phase 3 | 4,000 | saquinavir | Its name | ClinicalTrials.gov | |
| NCT00002334 | A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment | Phase 3 | 3,000 | saquinavir | Its name | ClinicalTrials.gov | |
| NCT00002333 | A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine | Phase 2 | 900 | saquinavir | Its name | ClinicalTrials.gov | |
| NCT00002378 | A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients | Phase 3 | 825 | saquinavir | Its name | ClinicalTrials.gov | |
| NCT00000914 | A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks | 800 | saquinavir | Its name | ClinicalTrials.gov |
1 to 10 of 69
See all 69 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Saquinavir/Ritonavir vs Lopinavir/Ritonavir: Number of Patients Who Discontinued Treatment Due to Abnormal Laboratory Parameters | 0 of 163 | 0 of 168 | 331 | NCT00105079 | Trial comparisons |
| Saquinavir/Ritonavir vs Lopinavir/Ritonavir: Number of Participants Assessed for Adverse Events (AEs) | 163 of 163 | 168 of 168 | 331 | NCT00105079 | Trial comparisons |
| Saquinavir/Ritonavir vs Lopinavir/Ritonavir: serious adverse events | 24 of 163 | 19 of 168 | 331 | NCT00105079 | Trial comparisons |
| ATV 300 mg / RTV vs LPV / RTV: Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 96 | 38 of 120 | 41 of 118 | 238 | NCT00035932 | Trial comparisons |
| ATV 300 mg / RTV vs LPV / RTV: Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 96 | 52 of 120 | 53 of 116 | 236 | NCT00035932 | Trial comparisons |
| ATV 300 mg / RTV vs LPV / RTV: Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96 | 61 of 120 | 57 of 113 | 233 | NCT00035932 | Trial comparisons |
| ATV 300 mg / RTV vs LPV / RTV: Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 96 | 61 of 120 | 58 of 113 | 233 | NCT00035932 | Trial comparisons |
| Normal Liver Function vs Moderate Hepatic Impairment: serious adverse events | 0 of 7 | 1 of 9 | 16 | NCT00435929 | Trial comparisons |
Papers from its trials23
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL114
GET https://conductscience.org/api/drugs/v1/CHEMBL114/trials?page=2